{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-22-006398","form_type":"8-K","ticker":"ABEO","cik":"0000318306","company_name":"ABEONA THERAPEUTICS INC.","filed_at":"2022-03-09T23:59:59+00:00","discovered_at":"2026-05-14T18:04:09.226347+00:00","generated_at":"2026-06-27T00:31:53.736135+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Abeona Therapeutics CFO Edward Carr resigns; Joseph Vazzano appointed new CFO","bullets":["Edward Carr resigns effective March 31, 2022; no disagreement with company.","Joseph Vazzano appointed CFO effective March 14, 2022; previously CFO of Avenue Therapeutics (ATXI).","Vazzano receives $360k base salary, 40% target bonus, 200k restricted shares; potential increase to $400k salary.","Vazzano to become principal financial and accounting officer on March 31, 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-22-006398","json":"https://secwatch.observer/filing/0001493152-22-006398.json","markdown":"https://secwatch.observer/filing/0001493152-22-006398.md","text":"https://secwatch.observer/filing/0001493152-22-006398.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/318306/000149315222006398/0001493152-22-006398-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/318306/000149315222006398/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-27T00:31:53.736135+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"d3a1bbe182","claim":"Edward Carr resigned as Chief Financial Officer at ABEONA THERAPEUTICS INC..","evidence_excerpt":"On March 3, 2022, Edward Carr, Chief Financial Officer and Chief Accounting Officer of Abeona Therapeutics Inc. (the “Company”), notified the Company of his resignation effective March 31, 2022.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/318306/000149315222006398/0001493152-22-006398-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Chief Financial Officer"}],"fact_type":"executive_change"},{"claim_id":"fa1e517040","claim":"Joseph Vazzano was appointed as Chief Financial Officer at ABEONA THERAPEUTICS INC..","evidence_excerpt":"Also on March 3, 2022, the Board appointed Joseph Vazzano as Chief Financial Officer effective March 14, 2022.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/318306/000149315222006398/0001493152-22-006398-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Financial Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}